These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 11890658)

  • 1. Matrix metalloproteinase inhibitors in rheumatic diseases.
    Close DR
    Ann Rheum Dis; 2001 Nov; 60 Suppl 3(Suppl 3):iii62-7. PubMed ID: 11890658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis.
    Jüngel A; Ospelt C; Lesch M; Thiel M; Sunyer T; Schorr O; Michel BA; Gay RE; Kolling C; Flory C; Gay S; Neidhart M
    Ann Rheum Dis; 2010 May; 69(5):898-902. PubMed ID: 19497915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical potential of matrix metalloproteinase inhibitors in the rheumatic disorders.
    Elliott S; Cawston T
    Drugs Aging; 2001; 18(2):87-99. PubMed ID: 11346130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinase knockout studies and the potential use of matrix metalloproteinase inhibitors in the rheumatic diseases.
    Milner JM; Cawston TE
    Curr Drug Targets Inflamm Allergy; 2005 Jun; 4(3):363-75. PubMed ID: 16101546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of progressive joint destruction in collagen-induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR255031.
    Ishikawa T; Nishigaki F; Miyata S; Hirayama Y; Minoura K; Imanishi J; Neya M; Mizutani T; Imamura Y; Naritomi Y; Murai H; Ohkubo Y; Kagayama A; Mutoh S
    Br J Pharmacol; 2005 Jan; 144(1):133-43. PubMed ID: 15644877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of progressive joint destruction in adjuvant induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR217840.
    Ishikawa T; Nishigaki F; Miyata S; Hirayama Y; Minoura K; Imanishi J; Neya M; Mizutani T; Imamura Y; Ohkubo Y; Mutoh S
    Eur J Pharmacol; 2005 Jan; 508(1-3):239-47. PubMed ID: 15680277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model.
    Nasu Y; Nishida K; Miyazawa S; Komiyama T; Kadota Y; Abe N; Yoshida A; Hirohata S; Ohtsuka A; Ozaki T
    Osteoarthritis Cartilage; 2008 Jun; 16(6):723-32. PubMed ID: 18226559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flavonoid quercetin-methotrexate combination inhibits inflammatory mediators and matrix metalloproteinase expression, providing protection to joints in collagen-induced arthritis.
    Haleagrahara N; Hodgson K; Miranda-Hernandez S; Hughes S; Kulur AB; Ketheesan N
    Inflammopharmacology; 2018 Oct; 26(5):1219-1232. PubMed ID: 29616452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic implications of the specific inhibition of causative matrix metalloproteinases in experimental colitis induced by dextran sulphate sodium.
    Kobayashi K; Arimura Y; Goto A; Okahara S; Endo T; Shinomura Y; Imai K
    J Pathol; 2006 Jul; 209(3):376-83. PubMed ID: 16552705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective matrix metalloproteinase (MMP) inhibition in rheumatoid arthritis--targetting gelatinase A activation.
    Jackson C; Nguyen M; Arkell J; Sambrook P
    Inflamm Res; 2001 Apr; 50(4):183-6. PubMed ID: 11392606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vanadate, an inhibitor of stromelysin and collagenase expression, suppresses collagen induced arthritis.
    Oliver SJ; Firestein GS; Arsenault L; Cruz TF; Cheng TP; Banquerigo ML; Boyle DL; Brahn E
    J Rheumatol; 2007 Sep; 34(9):1802-9. PubMed ID: 17696279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
    Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
    Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatic drugs.
    Mamehara A; Sugimoto T; Sugiyama D; Morinobu S; Tsuji G; Kawano S; Morinobu A; Kumagai S
    Kobe J Med Sci; 2010 Sep; 56(3):E98-107. PubMed ID: 21063156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis.
    Catrina AI; Lampa J; Ernestam S; af Klint E; Bratt J; Klareskog L; Ulfgren AK
    Rheumatology (Oxford); 2002 May; 41(5):484-9. PubMed ID: 12011369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of antiarthritic drug efficacies by monitoring active matrix metalloproteinase-3 (MMP-3) levels in collagen-induced arthritic mice using the MMP-3 probe.
    Lee A; Park K; Choi SJ; Seo DH; Kim K; Kim HS; Choi K; Kwon IC; Yoon SY; Youn I
    Mol Pharm; 2014 May; 11(5):1450-8. PubMed ID: 24673659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinases and TIMPs: properties and implications for the rheumatic diseases.
    Cawston T
    Mol Med Today; 1998 Mar; 4(3):130-7. PubMed ID: 9575496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid.
    Johnson DR; Stebulis JA; Rossetti RG; Burstein SH; Zurier RB
    J Cell Biochem; 2007 Jan; 100(1):184-90. PubMed ID: 16927387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.
    Baxter AD; Bhogal R; Bird J; Keily JF; Manallack DT; Montana JG; Owen DA; Pitt WR; Watson RJ; Wills RE
    Bioorg Med Chem Lett; 2001 Jun; 11(11):1465-8. PubMed ID: 11378378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.
    Baragi VM; Becher G; Bendele AM; Biesinger R; Bluhm H; Boer J; Deng H; Dodd R; Essers M; Feuerstein T; Gallagher BM; Gege C; Hochgürtel M; Hofmann M; Jaworski A; Jin L; Kiely A; Korniski B; Kroth H; Nix D; Nolte B; Piecha D; Powers TS; Richter F; Schneider M; Steeneck C; Sucholeiki I; Taveras A; Timmermann A; Van Veldhuizen J; Weik J; Wu X; Xia B
    Arthritis Rheum; 2009 Jul; 60(7):2008-18. PubMed ID: 19565489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural joint damage and hand bone loss in patients with rheumatoid arthritis.
    Ørnbjerg LM
    Dan Med J; 2018 Mar; 65(3):. PubMed ID: 29510810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.